In focus · trending topic

LCA10

20 stories · following the connections

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

By Nasdaq OMXMar 27, 2017, 11:02 AM UTC

ProQR to Present at Two Upcoming Investor Conferences in March

By Nasdaq OMXMar 1, 2017, 12:01 PM UTC

On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

By Nasdaq OMXFeb 27, 2017, 12:01 PM UTC